No Data
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause) of SAAFD. ＜3557＞ Large exercise of the 9th subscription rights (with exercise price adjustment clause) of U&C from the 4th, number of shares delivered, 0.07 million, 2000 shares. ＜4576＞ Approval obtained in Thailand for the glaucoma and ocular hypertension treatment "Grau Alpha combination eye drops (domestic product name)" of DWTI. ＜4586＞ Termination of joint research contract with Medrec Fanpepp. ＜4881＞ Soleasia's downward revision, current period operations.
Medrx Sees FY Loss Y846.00M
Medrx: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.
Hot stocks digest (morning session): Sakura, LITALICO, Flutta, etc.
Stocks hit the daily limit. The company announced its semi-annual financial results the day before, with operating profit reaching 1.3 billion yen, a 5.2-fold increase compared to the same period last year, surpassing the upward revised figure of 1.1 billion yen on September 20th.
No Data